Company Overview and News

2
TRIL / Trillium Therapeutics Inc. FORM 6-K (Current Report of Foreign Issuer)

2018-09-12 sec.gov - 1
Trillium Therapeutics Inc. - Form 6-K - Filed by newsfilecorp.com UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ___________________ FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of September 2018 Commission File Number:
TRIL

1
Trillium Therapeutics Announces Data Presentations at Upcoming Scientific Meetings

2018-09-12 globenewswire
TORONTO, Sept. 12, 2018 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (Nasdaq:TRIL) (TSX:TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, announced today that the company is scheduled to present an update on the company’s TTI-621 clinical programs at two upcoming scientific conferences.
TRIL

2
Trillium to Present at the 20th Annual Rodman & Renshaw Global Investment Conference

2018-08-30 globenewswire - 1
TORONTO, Aug. 30, 2018 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, announced today that it will be featured as a presenting company at the 20th Annual Rodman & Renshaw Global Investment Conference, sponsored by H.C. Wainwright & Co., LLC. The conference is being held on September 4-6, 2018 at the St.
TRIL

3
TRIL / Trillium Therapeutics Inc. FORM 6-K (Current Report of Foreign Issuer)

2018-08-30 sec.gov - 2
Trillium Therapeutics Inc. - Form 6-K - Filed by newsfilecorp.com UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ___________________ FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of August, 2018 <
TRIL

1
TRIL / Trillium Therapeutics Inc. FORM 6-K (Current Report of Foreign Issuer)

2018-08-08 sec.gov
Trillium Therapeutics Inc. - Form 6-K - Filed by newsfilecorp.com UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ___________________ FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of August, 2018 <
TRIL

6
47 Scoop: Trillium Bleeds, Surface Hemorrhages, And Forty Seven Throws In The $47 Million Towel On Synthon Lawsuit

2018-08-01 seekingalpha - 1
Forty Seven to pay $47 million in upfront/milestone payments and drop all lawsuits against Synthon/Sanquin in exchange for a non-exclusive sublicense to IP covering antibody combinations.
SURF CELG FTSV TRIL BMY

10
Company Profile: Surface Oncology

2018-07-22 seekingalpha - 1
SURF has a business-minded management with a strong track record of raising capital, shoring up its balance sheet with $200 million cash through its spring IPO and partnership w/ Novartis.
AZN AZN SURF CELG NVS CRVS FTSV TRIL

3
Company Spotlight: Trillium Therapeutics

2018-07-18 seekingalpha
Trillium Therapeutics (TRIL) is a Canadian company developing a novel cancer immunotherapy consisting of a SIRPaFc fusion protein targeting CD47, a next-generation checkpoint inhibitor of the innate immune system.
HSC SURF FTSV TRIL

4
Company Spotlight: Forty Seven

2018-07-11 seekingalpha - 1
Forty Seven is well-positioned to continue advancing their anti-CD47 antibody, Hu5F9, towards a potential first-in-class checkpoint inhibitor targeting the innate immune system.
MRK SURF FTSV TRIL BMY

23
Forty Seven IPO: Google Has A Stake, But Other Competitors Trade At Lower Valuations

2018-07-06 seekingalpha - 7
Entities affiliated with Google own 5.2% stake in the company. Clients of Wellington Management Company have 6.8% stake as well.
ORPHF ABT MKGAF AMGN CELGZ GILD SURF GOOG TRIL ABT RHHBF ARTH RHHVF MKGAY MRK CELG RHHBY FTSV PDLI

1
TRIL / Trillium Therapeutics Inc. null

2018-07-05 sec.gov
begin 644 filename1.pdf M)5!$1BTQ+C4-)>+CS],-"C<@,"!O8FH-/#PO3&EN96%R:7IE9" [email protected],S(P M,3$O3R [email protected],C
TRIL

1
TRIL / Trillium Therapeutics Inc. null

2018-07-05 sec.gov
Trillium Therapeutics Inc. - SEC Correspondence - Filed by newsfilecorp.com May 29, 2018 Division of Corporation Finance U.S. Securities and Exchange Commission 100 F Street, NE Washington, DC 20549-3628 Attention: Christine Westbrook Re:
TRIL

6
Targeting CD47: To Eat Or Not To Eat?

2018-07-03 seekingalpha - 1
CD47-directed therapies offer a novel immuno-oncology strategy for engaging the innate immune system in a variety of tumor types.
SURF CELG FTSV TRIL

9
TRIL / Trillium Therapeutics Inc. FORM 6-K (Current Report of Foreign Issuer)

2018-06-25 sec.gov - 3
Trillium Therapeutics Inc. - Form 6-K - Filed by newsfilecorp.com UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ___________________ FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of June 2018
TRIL

9
TRIL / Trillium Therapeutics Inc. SUPPL

2018-06-20 sec.gov - 3
Trilliuam Therapeutics Inc. - Prospectus Supplement - Filed by newsfilecorp.com Filed pursuant to General Instructions II.L. of Form F-10 File No. 333-222085 No securities regulatory authority has expressed an opinion about these securities and it is an offence to claim otherwise. This prospectus supplement, together with the accompanying short form base shelf prospectus dated January 5, 2018 to which this prospectus supplement relates, as amended or supplemented, and each document deemed to be incorporated by ref
TRIL

Related Articles

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

2018-09-18 - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

AGRX: Agile Therapeutics Analysis and Research Report

2018-09-18 - Asif

Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...

Silicon Investor Message Boards

This table lists all message boards related to TRIL / Trillium Therapeutics Inc. on message board site Silicon Investor.

Trillium Therapeutics Trillium Therapeutics Trillium Therapeutics The World���s Biggest Wealth Fund Hits $1 Trillion The World���s Biggest Wealth Fund Hits $1 Trillion The World���s Biggest Wealth Fund Hits $1 Trillion
$20 Trillion in debt and more tax cuts? When will it end? $20 Trillion in debt and more tax cuts? When will it end? $20 Trillion in debt and more tax cuts? When will it end? Discuss the Fiscal Cliff. Obamau0027s opening bid: $1.6 trillion Discuss the Fiscal Cliff. Obamau0027s opening bid: $1.6 trillion Discuss the Fiscal Cliff. Obamau0027s opening bid: $1.6 trillion
CONSOLIDATED TRILOGY/CTJ/VSE: HUGE POTENTIAL IN CHILE. CONSOLIDATED TRILOGY/CTJ/VSE: HUGE POTENTIAL IN CHILE. CONSOLIDATED TRILOGY/CTJ/VSE: HUGE POTENTIAL IN CHILE. Go2Net Long List of Go2Netrillionaires (GNET) Go2Net Long List of Go2Netrillionaires (GNET) Go2Net Long List of Go2Netrillionaires (GNET)
Tri-Valley Corp. (OTC BB: TRIL) Tri-Valley Corp. (OTC BB: TRIL) Tri-Valley Corp. (OTC BB: TRIL) EKHO Project EKHO Project EKHO Project
Trillium Trillium Trillium BB Stocks Less Than 5 Cents with Trillion Share Floats BB Stocks Less Than 5 Cents with Trillion Share Floats BB Stocks Less Than 5 Cents with Trillion Share Floats
CUSIP: 89620X506